FindTrial
Sign In

Evaluation of inflammatory substances in the blood of patients with recurrent glioblastoma in treatment with inhalation of perillyl alcohol associated with reduced carbohydrate diet and supplementation with omega 3

Evatuation of the metabolomic profile of patients with recurrent glioblastoma in treatment with perillyl alcohol intranasal administration associated with the ketogenic diet and dha suplementation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3byz2c
Enrollment
Unknown
Registered
2018-01-24
Start date
2018-01-26
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Interventions

Group 2: 20 participants who will receive ketogenic diet and dha supplement for 2 months, and will take 3 dha capsules per day, 30 minutes before main meals Control group: 20 participants who will al
Dietary supplement
Other
E02.642.249.650
SP6.051.227

Sponsors

Hospital Universitário Antônio Pedro
Lead Sponsor
Instituto de Química da Universidade de São Paulo
Collaborator

Eligibility

Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Adults with glioblastoma; submitted to surgical procedure with the partial withdrawal of the tumor; who presented recurrences and are under chemotherapeutic treatment.

Exclusion criteria

Exclusion criteria: Participants who initiate immunotherapeutic treatment; or develop autoimmune; hepatic or renal disease; or discontinue the ketogenic diet; perillyl alcohol inhalation or supplement will be excluded.

Design outcomes

Primary

MeasureTime frame
Survival free of progression of participants, monitored by magnetic resonance imaging after 1 year of study.—

Secondary

MeasureTime frame
The combined treatment is expected to stabilize tumor growth, which will be checked at baseline and after 2 months of study.—

Countries

Brazil

Contacts

Public ContactClovis Pereira da Fonseca

Universidade Federal Fluminense

clovis.orlando@uol.com.br+55 (21) 2629 9000

Outcome results

None listed

Source: REBEC (via WHO ICTRP)